CR8698A - Anticuerpos monoclonales al factor de crecimiento de hepatocito - Google Patents
Anticuerpos monoclonales al factor de crecimiento de hepatocitoInfo
- Publication number
- CR8698A CR8698A CR8698A CR8698A CR8698A CR 8698 A CR8698 A CR 8698A CR 8698 A CR8698 A CR 8698A CR 8698 A CR8698 A CR 8698A CR 8698 A CR8698 A CR 8698A
- Authority
- CR
- Costa Rica
- Prior art keywords
- growth factor
- hepatocite
- monoclonal antibodies
- pharmaceutical composition
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invencion es concerniente con un anticuerpo monoclonal neutralizante al factor crecimiento de hepatocito, una composicion farmaceutica que comprende el mismo y metodo de tratamiento que comprenden administrar tal composicion farmaceutica a un paciente, tal como para inhibir glioblastoma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/825,060 US20040208876A1 (en) | 2003-04-18 | 2004-04-15 | Monoclonal antibodies to hepatocyte growth factor |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8698A true CR8698A (es) | 2007-12-17 |
Family
ID=35320045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8698A CR8698A (es) | 2004-04-15 | 2006-10-19 | Anticuerpos monoclonales al factor de crecimiento de hepatocito |
Country Status (26)
Country | Link |
---|---|
US (5) | US20040208876A1 (es) |
EP (2) | EP2204191A1 (es) |
JP (2) | JP4594381B2 (es) |
KR (1) | KR101072736B1 (es) |
CN (1) | CN1964738A (es) |
AT (1) | ATE473760T1 (es) |
AU (1) | AU2004319276C1 (es) |
BR (1) | BRPI0418745A (es) |
CA (1) | CA2563080C (es) |
CR (1) | CR8698A (es) |
CY (1) | CY1110783T1 (es) |
DE (1) | DE602004028168D1 (es) |
DK (1) | DK1734995T3 (es) |
ES (1) | ES2346886T3 (es) |
HK (1) | HK1094167A1 (es) |
HR (1) | HRP20100521T1 (es) |
IL (1) | IL178474A (es) |
MX (1) | MXPA06011822A (es) |
NO (1) | NO20065227L (es) |
NZ (1) | NZ550324A (es) |
PL (1) | PL1734995T3 (es) |
PT (1) | PT1734995E (es) |
RU (1) | RU2361879C2 (es) |
SI (1) | SI1734995T1 (es) |
WO (1) | WO2005107800A1 (es) |
ZA (1) | ZA200609407B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
TWI476206B (zh) * | 2003-07-18 | 2015-03-11 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
MX2007001470A (es) * | 2004-08-05 | 2007-03-26 | Genentech Inc | Antagonistas anti-cmet humanizados. |
JP2008545753A (ja) * | 2005-06-02 | 2008-12-18 | ギャラクシー バイオテック, エルエルシー | 抗体で脳腫瘍を処置する方法 |
WO2007043641A1 (ja) | 2005-10-14 | 2007-04-19 | Fukuoka University | 膵島移植における移植膵島障害抑制剤 |
BRPI0617664B8 (pt) | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
AR057941A1 (es) * | 2005-11-25 | 2007-12-26 | Univ Keio | Agentes terapeuticos para el cancer de prostata |
EP3135298B1 (en) | 2006-01-27 | 2018-06-06 | Keio University | Therapeutic agents for diseases involving choroidal neovascularization |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
CN101495146B (zh) | 2006-04-07 | 2012-10-17 | 国立大学法人大阪大学 | 肌肉再生促进剂 |
EP2029627B1 (en) | 2006-06-02 | 2011-11-16 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (hgf) binding proteins |
SG158112A1 (en) | 2006-06-02 | 2010-01-29 | Aveo Pharmaceuticals Inc | Hepatocyte growth factor (hgf) binding proteins |
TWI438208B (zh) | 2007-01-23 | 2014-05-21 | Chugai Pharmaceutical Co Ltd | 抑制慢性排斥反應之藥劑 |
EP2170268A2 (en) * | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
CL2009000843A1 (es) * | 2008-04-11 | 2009-07-24 | Galaxy Biotech Llc | Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet. |
EP2288383A1 (en) * | 2008-05-14 | 2011-03-02 | Amgen, Inc | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
KR101665729B1 (ko) | 2008-06-05 | 2016-10-12 | 국립연구개발법인 고쿠리츠간켄큐센터 | 신경침윤 억제제 |
PA8849001A1 (es) * | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
WO2010119991A2 (en) | 2009-04-17 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Novel method of treating cancer |
CN101555912B (zh) * | 2009-04-29 | 2012-10-03 | 深圳市特辰科技股份有限公司 | 一种转轮式自锁安全制动装置及其工作方法 |
EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
DK2578231T3 (da) | 2010-05-28 | 2022-12-12 | Chugai Pharmaceutical Co Ltd | Antitumor-t-celle-reaktionsforstærker |
WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
EP2621483A1 (en) | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
MX2013014687A (es) | 2011-06-30 | 2014-02-17 | Genentech Inc | Formulaciones de anticuerpo anti-c-met. |
CZ2011514A3 (cs) * | 2011-08-19 | 2013-01-23 | Invos, Spol. S R. O. | Biokontejner pro sber bioodpadu a komunálního odpadu |
CN103974720A (zh) | 2011-09-09 | 2014-08-06 | 安姆根有限公司 | C-met蛋白质用于预测抗肝细胞生长因子(“hgf”)抗体在食管癌和胃癌患者中的功效的用途 |
EP2758430A4 (en) | 2011-09-20 | 2015-06-03 | Lilly Co Eli | ANTI-C-MET ANTIBODY |
JP6224586B2 (ja) | 2012-07-10 | 2017-11-01 | 武田薬品工業株式会社 | 注射用製剤 |
EP2708556B1 (en) | 2012-09-12 | 2018-11-07 | Samsung Electronics Co., Ltd | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases |
US9481725B2 (en) | 2013-03-14 | 2016-11-01 | Alderbio Holdings, Llc | Antibodies to HGF and compositions containing |
TW201444868A (zh) * | 2013-03-14 | 2014-12-01 | Alder Biopharmaceuticals Inc | Hgf抗體及其組成物 |
WO2015031578A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Hgf assay |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US722041A (en) * | 1902-11-24 | 1903-03-03 | Mail Belting Company | Conveyer-belt. |
JP2564486B2 (ja) | 1986-07-14 | 1996-12-18 | 修治 橋本 | 肝細胞増殖因子 |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
GB9003621D0 (en) | 1990-02-16 | 1990-04-11 | Imp Cancer Res Tech | Protein factor |
GB9009548D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Chimeric antibody and method |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
US5707624A (en) | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US5646036A (en) | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
AU729029B2 (en) * | 1996-07-03 | 2001-01-25 | Genentech Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
AU5588099A (en) | 1998-08-28 | 2000-03-21 | Dendreon Corporation | Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody |
WO2001034650A1 (en) | 1999-11-09 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services | Hgf-sf monoclonal antibody combinations |
EP1423432A4 (en) | 2001-07-26 | 2006-01-11 | Lilly Co Eli | ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA) |
WO2003057155A2 (en) | 2001-12-27 | 2003-07-17 | Van Andel Research Institute | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
WO2004019991A2 (en) * | 2002-08-30 | 2004-03-11 | F. Hoffmann-La Roche Ag | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma |
US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
US20040208876A1 (en) | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
PL1636593T3 (pl) | 2003-06-06 | 2009-08-31 | Genentech Inc | Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met. |
WO2005007193A2 (en) | 2003-07-07 | 2005-01-27 | Vande Woude, George, F. | Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
TWI476206B (zh) * | 2003-07-18 | 2015-03-11 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
KR100556660B1 (ko) * | 2003-11-11 | 2006-03-10 | 국립암센터 | Hgf의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
JP2008545753A (ja) | 2005-06-02 | 2008-12-18 | ギャラクシー バイオテック, エルエルシー | 抗体で脳腫瘍を処置する方法 |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
-
2004
- 2004-04-15 US US10/825,060 patent/US20040208876A1/en not_active Abandoned
- 2004-08-13 RU RU2006140257/13A patent/RU2361879C2/ru not_active IP Right Cessation
- 2004-08-13 MX MXPA06011822A patent/MXPA06011822A/es active IP Right Grant
- 2004-08-13 DE DE602004028168T patent/DE602004028168D1/de active Active
- 2004-08-13 DK DK04781281.3T patent/DK1734995T3/da active
- 2004-08-13 KR KR1020067023964A patent/KR101072736B1/ko not_active IP Right Cessation
- 2004-08-13 BR BRPI0418745-8A patent/BRPI0418745A/pt not_active IP Right Cessation
- 2004-08-13 PT PT04781281T patent/PT1734995E/pt unknown
- 2004-08-13 JP JP2007508323A patent/JP4594381B2/ja not_active Expired - Fee Related
- 2004-08-13 AU AU2004319276A patent/AU2004319276C1/en not_active Ceased
- 2004-08-13 NZ NZ550324A patent/NZ550324A/en not_active IP Right Cessation
- 2004-08-13 EP EP10160203A patent/EP2204191A1/en not_active Withdrawn
- 2004-08-13 AT AT04781281T patent/ATE473760T1/de active
- 2004-08-13 CN CNA200480042750XA patent/CN1964738A/zh active Pending
- 2004-08-13 PL PL04781281T patent/PL1734995T3/pl unknown
- 2004-08-13 SI SI200431468T patent/SI1734995T1/sl unknown
- 2004-08-13 ES ES04781281T patent/ES2346886T3/es active Active
- 2004-08-13 EP EP04781281A patent/EP1734995B1/en active Active
- 2004-08-13 CA CA2563080A patent/CA2563080C/en not_active Expired - Fee Related
- 2004-08-13 WO PCT/US2004/026565 patent/WO2005107800A1/en active Application Filing
- 2004-08-13 ZA ZA200609407A patent/ZA200609407B/xx unknown
-
2006
- 2006-10-05 IL IL178474A patent/IL178474A/en not_active IP Right Cessation
- 2006-10-19 CR CR8698A patent/CR8698A/es unknown
- 2006-11-14 NO NO20065227A patent/NO20065227L/no not_active Application Discontinuation
-
2007
- 2007-02-05 HK HK07101333.7A patent/HK1094167A1/xx unknown
- 2007-02-23 US US11/710,009 patent/US7494650B2/en not_active Expired - Fee Related
- 2007-06-13 US US11/818,305 patent/US7687063B2/en not_active Expired - Fee Related
-
2008
- 2008-12-22 US US12/342,059 patent/US20090104192A1/en not_active Abandoned
-
2010
- 2010-08-03 JP JP2010174810A patent/JP2011012067A/ja not_active Withdrawn
- 2010-08-30 CY CY20101100789T patent/CY1110783T1/el unknown
- 2010-09-22 HR HR20100521T patent/HRP20100521T1/hr unknown
-
2011
- 2011-06-14 US US13/160,444 patent/US20120064066A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
WO2010054265A3 (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
EA200700202A1 (ru) | Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей | |
CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
ATE536188T1 (de) | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon | |
EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
CY1113630T1 (el) | Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωn | |
CA2725873A1 (en) | Monoclonal antibodies to basic fibroblast growth factor | |
DK2109623T3 (da) | Cancerbehandling med anti-IL-1-antistoffer | |
ATE437186T1 (de) | Anti-epcam-immunoglobuline | |
EA200970586A1 (ru) | Антитела к цитомегаловирусу человека (hcmv) | |
DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
ATE503476T1 (de) | Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind | |
TW200740845A (en) | Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue | |
TR200902344T1 (tr) | Anti-epidermal büyüme faktörü reseptör antikorları ile terapinin etkisinin geliştirilmesi için terapötik bileşimler. | |
DE60229624D1 (de) | Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion |